This is a working overview of Reference standard, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Eddy copyrighted her book, then called The Science of Life, in July 1874. Three of her students, George Barry, Elizabeth Newhall and Daniel Spofford, paid a Boston printer, W. F. Brown and Company, $2,200 to produce the first edition. The printer began work in September 1874, but stopped whenever the advance payment ran out, so progress was slow. The book—Science and Health by Mary Baker Glover, with eight chapters and 456 pages—finally appeared on October 30, 1875, published in the name of the Christian Science Publishing Company. The book was positively received by Amos Bronson Alcott, who in 1876 wrote to Eddy that she had "reaffirm[ed] in modern phrase the Christian revelations," and that he was pleased it had been written by a woman. The printer's proofreading had been poor. Martin Gardner called the first edition a "chaotic patchwork of repetitious, poorly paragraphed topics," with spelling, punctuation and grammatical mistakes. Eddy changed printers for the second edition, which was also poorly proofread, and for the third edition in 1881 switched again, this time to John Wilson & Sons, University Press, Cambridge, MA. John Wilson and his successor, William Dana Orcutt, continued to print the book until after Eddy's death. To the 6th edition in 1883, Eddy added with a Key to the Scriptures (later retitled with Key to the Scriptures), a 20-page glossary containing her definitions of biblical terms. The book sold 15,000 copies between 1875 and 1885. In August 1885, on the advice of John Wilson, she hired one of his proofreaders, the Rev.
National Security Council spokesman John Kirby responded by accusing Lula of "parroting Russian and Chinese propaganda", describing his comments as "simply misguided" and "suggesting the United States and Europe are somehow not interested in peace, or that we share responsibility for the war." On 19 May 2023, Lula said he was "upset" after Ukrainian president Volodymyr Zelesnkyy did not attend a meeting between both on the sidelines of the G7 Summit in Hiroshima. On 22 May, Danish foreign minister Lars Løkke Rasmussen said that Denmark was interested in hosting a summit aimed at "finding peace between Ukraine and Russia". but "it is necessary to build interest and involvement from countries like India, Brazil and China." In September 2023, Lula and Ukrainian president Volodymyr Zelenskyy met on the sidelines of the 78th United National General Assembly (UNGA), in New York; Lula pledged to maintain an open dialogue between their countries to end the war.
=== Phase 1/2 === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – opioid-related disorders Ibogaine (DMX-1002; IBX-210) – various actions/unknown mechanism of action and oneirogen/hallucinogen – opioid-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – alcoholism PT-00114 (PT100114; TCAP-1) – corticotropin-releasing hormone (CRH) inhibitor – opioid-related disorders
=== 1918 uprisings === In mid-1918, the Union moved from underground organization to open insurrection. It played a central role in organizing a series of anti-Bolshevik uprisings, most notably in Yaroslavl, but also in Rybinsk, Murom, and Elatma. These uprisings formed part of a broader effort to ignite coordinated resistance against the Bolshevik government. Additional revolts were reportedly planned in Moscow and Kazan, but arrests of members of the organization in May 1918 disrupted these plans before they could be carried out. The uprisings were suppressed by Soviet forces, and the Union's operational structure inside Russia was effectively broken apart in the aftermath.
Sources: en.wikipedia.org
==== Record GDP growth ==== At the end of 2023, Brazil once again became one of the ten largest economies in the world, according to the IMF, the country had dropped out of the ranking between 2019 and 2022, when it fell to 13th place. Also at the end of 2023, the Brazilian trade balance marked the largest surplus in its history, with 98 billion dollars, a significant jump in relation to the 2022 surplus, of 61 billion dollars, which was the previous record. This increase was sustained by the 1.7% increase in exports and the 11.7% drop in imports, resulting from the 8.8% decline in the price of imported items, such as fertilizers, whose price decreased by 44.9% in comparison with 2022. The current account showed a deficit of 28 billion dollars in 2023 and direct investment in the country totaled 62 billion dollars. Released on 1 March 2024, Brazil's GDP grew 2.9% in the first year of the Lula government. The increase was driven especially by the super harvest in the agricultural sector, the recovery of the services sector and the job market, the maintenance of social spending, and the expansion of fiscal space opened by the New Fiscal Framework; growth surpassed the first year of the Bolsonaro, Temer, Dilma 2, Lula 1 and FHC 2 governments, being lower only than the first year of the Dilma 1, Lula 2 and FHC 1 governments.
=== Non-enzymatic additions in vitro === biotinylation: covalent attachment of a biotin moiety using a biotinylation reagent, typically for the purpose of labeling a protein. carbamylation: the addition of isocyanic acid to a protein's N-terminus or the side-chain of Lys or Cys residues, typically resulting from exposure to urea solutions. oxidation: addition of one or more oxygen atoms to a susceptible side-chain, principally of Met, Trp, His or Cys residues. Formation of disulfide bonds between Cys residues. pegylation: covalent attachment of polyethylene glycol (PEG) using a pegylation reagent, typically to the N-terminus or the side-chains of Lys residues. Pegylation is used to improve the efficacy of protein pharmaceuticals.
=== 1918 uprisings === In mid-1918, the Union moved from underground organization to open insurrection. It played a central role in organizing a series of anti-Bolshevik uprisings, most notably in Yaroslavl, but also in Rybinsk, Murom, and Elatma. These uprisings formed part of a broader effort to ignite coordinated resistance against the Bolshevik government. Additional revolts were reportedly planned in Moscow and Kazan, but arrests of members of the organization in May 1918 disrupted these plans before they could be carried out. The uprisings were suppressed by Soviet forces, and the Union's operational structure inside Russia was effectively broken apart in the aftermath.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.